All articles tagged with #aiolos bio
GSK has announced its acquisition of Aiolos Bio, a clinical-stage asthma drugmaker, for an upfront payment of $1 billion with the potential for an additional $400 million based on meeting milestones. This purchase comes just three months after Aiolos Bio emerged as a startup with a significant private financing round of $245 million, making it one of the fastest startup unveilings to buyout journeys in recent biotech memory.
GSK has entered into an agreement to acquire Aiolos Bio for $1 billion upfront and up to $400 million in milestone payments, gaining access to AIO-001, a potentially best-in-class, long-acting anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody. This acquisition expands GSK’s respiratory pipeline and offers the potential to redefine the standard-of-care for asthma treatment, with AIO-001 targeting the TSLP pathway and demonstrating initial safety and tolerability in early studies. The transaction is subject to regulatory clearances and underscores GSK’s commitment to advancing respiratory therapies.
Aiolos Bio, founded by former Genentech executives, has raised $245 million in a Series A funding round to advance an asthma drug licensed from China. The startup plans to initiate a Phase II asthma study next year for its anti-TSLP antibody, which is its sole drug candidate. Aiolos Bio's CEO, Khurem Farooq, previously led Gyroscope Therapeutics, which was acquired by Novartis in December 2021.